Lung Cancer

KRAS mutation targeting offers better outcomes in NSCLC

The most common of the KRAS mutations in non-small cell lung cancer (NSCLC) has been flagged as potentially targetable and may therefore help improve patient outcomes. A real-world study from the Thoracic Malignancies Cohort at Peter MacCallum Cancer Centre comprised 346 patients with metastatic or recurrent non-squamous NSCLC who had available KRAS mutation test results ...

Already a member?

Login to keep reading.

© 2021 the limbic